Gait speed, hemoglobin, serum albumin, exhaustion, and depression were significantly worse in patients with all types of cancers than in the pair-matched controls.
Among patients with bladder, upper tract urothelial carcinoma, and renal cell carcinoma, overall survival was significantly shorter in patients with an FDS over 2.30 than in those with a lower score.
Among patients with prostate cancer, overall survival was significantly shorter in patients with an FDS over 3.30 than in those with a lower score.
Patients with a 0 on the sum of positive components in the Fried criteria scored an FDS of 1.75. A Fried of 1 corresponded to an FDS of 3.28, a Fried of 2 corresponded to an FDS of 3.74, and a Fried of 3 corresponded to an FDS of 6.73. The differences were statistically significant (p<.001).
The tool can help patients and physicians make more informed decisions, Dr. Hatakeyama said. Based on such findings, a surgeon might decide not to perform a procedure, he said.
"We need more data, but it suggests that possibility,” said Dr. Hatakeyama.